Psyence Biomedical (PBM) Notes Payables (2023 - 2024)
Psyence Biomedical (PBM) posted Notes Payables of $1.3 million for Q3 2024, down 15.02% on a QoQ basis from $1.5 million in Q1 2024, and up 219.53% year-over-year from $392100.0 in Q4 2023.
Powered by 
Analysis
Psyence Biomedical (PBM) Notes Payables (2023 - 2024) Analysis & Trends
Psyence Biomedical has reported Notes Payables for 2 years, with the latest figure at $1.3 million in Q3 2024.
- On a quarterly basis, Notes Payables rose 219.53% year-over-year to $1.3 million in Q3 2024; TTM through Sep 2024 was $1.3 million, a 219.53% increase from a year earlier, with the FY2024 full-year figure at $1.5 million, changed N/A from the prior year.
- Notes Payables was $1.3 million for Q3 2024 at Psyence Biomedical, down from $1.5 million in the prior quarter.
- The five-year high for Notes Payables was $1.5 million in Q1 2024, with the low at $392100.0 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.59 Bn | 192.60 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.21 Bn | 177.03 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.41 Bn | 123.56 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.94 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.60 Bn | 55.41 Bn | 1.37 Bn |
| 6 | Moderna | 53.61 Bn | 48.47 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.49 Bn | 30.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.83 Bn | 30.54 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.14 Bn | 29.14 Bn | 1.16 Mn |
| 10 | Psyence Biomedical | 2.64 Mn | 2.64 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 1.25 Mn |
| Mar 31, 2024 | 1.47 Mn |
| Sep 30, 2023 | 392,100.00 |